Date published: 2025-11-26

1-800-457-3801

SCBT Portrait Logo
Seach Input

SLURP-2 Inhibitors

SLURP-2 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of SLURP-2 (Secreted Ly6/uPAR-Related Protein 2), a member of the Ly6/uPAR superfamily. SLURP-2 is a small, secreted protein predominantly expressed in epithelial tissues such as the skin and mucous membranes. It plays a significant role in modulating various cellular processes, including cell proliferation, differentiation, and immune responses. SLURP-2 functions as a ligand for nicotinic acetylcholine receptors (nAChRs), particularly the α7 subtype, influencing intracellular signaling pathways that affect keratinocyte behavior and epidermal homeostasis. By interacting with these receptors, SLURP-2 can regulate calcium influx, gene expression, and cytokine release, thereby impacting cell communication and function within epithelial layers.

Inhibitors of SLURP-2 work by interfering with its ability to bind to nAChRs or by disrupting its structural integrity, thus modulating downstream signaling pathways. These compounds may bind directly to SLURP-2, preventing it from associating with its receptors, or they might block the receptor sites to hinder SLURP-2 binding. By inhibiting SLURP-2, these substances can alter cellular processes such as proliferation and differentiation, potentially affecting the balance of cell growth and maturation in epithelial tissues. Research into SLURP-2 inhibitors provides valuable insights into the molecular mechanisms underlying cell signaling in the skin and other epithelial tissues, enhancing the understanding of how proteins like SLURP-2 contribute to the regulation of cellular function and tissue homeostasis.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

hydroxychloroquine

118-42-3sc-507426
5 g
$56.00
1
(0)

An immunomodulatory drug that may affect SLURP2 activity indirectly through its anti-inflammatory properties.

Methotrexate

59-05-2sc-3507
sc-3507A
100 mg
500 mg
$92.00
$209.00
33
(5)

An immunosuppressant that could modulate immune-related pathways and potentially influence SLURP2 activity.

Cyclosporin A

59865-13-3sc-3503
sc-3503-CW
sc-3503A
sc-3503B
sc-3503C
sc-3503D
100 mg
100 mg
500 mg
10 g
25 g
100 g
$62.00
$90.00
$299.00
$475.00
$1015.00
$2099.00
69
(5)

An immunosuppressive agent that might alter immune responses, potentially affecting SLURP2-associated processes.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

A kinase inhibitor that targets multiple pathways and could indirectly influence SLURP2 activity via anti-cancer mechanisms.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

An mTOR inhibitor that may impact SLURP2 activity through immune regulation and anti-proliferative effects.

Thalidomide

50-35-1sc-201445
sc-201445A
100 mg
500 mg
$109.00
$350.00
8
(0)

Has immunomodulatory effects that could indirectly affect SLURP2 through modulation of inflammatory responses.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

A proteasome inhibitor that could influence cellular pathways associated with SLURP2 activity in the context of cancer.

Lenalidomide

191732-72-6sc-218656
sc-218656A
sc-218656B
10 mg
100 mg
1 g
$49.00
$367.00
$2030.00
18
(1)

An immunomodulatory drug that might affect SLURP2 by modulating the immune microenvironment.

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

A Bruton's tyrosine kinase inhibitor that may indirectly impact SLURP2 activity through immune pathway modulation.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$115.00
$415.00
11
(1)

Targets BRAF V600E mutation, potentially affecting pathways associated with SLURP2 in melanoma.